Observational studyJournal of Crohn's & colitis2025
Real-world evaluation of MRI fistula volume as a radiological biomarker of disease activity in perianal fistulizing Crohn's disease.
Observational study in Journal of Crohn's & colitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Imaging endpoints in inflammatory bowel disease: current evidence and future directions for ultrasound and MRI.BMC medicine · 2026Review
- Advancement flaps in perianal fistulizing Crohn's disease: technical steps and current evidence.Techniques in coloproctology · 2026Review
- VALIDATE-PERIANAL: an international real-world multi-centre exploratory validation of the TOpClass definition of a radiologically healed fistula in perianal fistulising Crohn's disease.Insights into imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe TOpClass classification for perianal fistulizing Crohn's disease (pfCD) facilitates tailored treatment to clinical state and patient goals. MRI is central to pfCD assessment, but existing indices are limited in predicting disease classification and trajectory. This study evaluated MRI fistula volume as a radiological biomarker and its longitudinal association with pfCD class.
methodsWe conducted a retrospective cohort study of 51 consecutive pfCD patients who underwent a baseline pelvic MRI in 2010 with ≥1 follow-up MRI. pfCD class was assigned at baseline, short- and long-term follow-up (median 10 years). A gastrointestinal radiologist, blinded to clinical data, measured active MRI fistula volume on T2-weighted axial sequences at each timepoint using ITK-Snap. The primary outcome was the association between volume and pfCD Class. Secondary outcomes included identification of volume thresholds discriminating clinical state/class via ROC analysis.
resultsOf 51 included patients (mean age 34.5), the majority had complex fistulae (92.1%) and 71% patients were TOpClass 2b, with 35% changing class during follow-up. MRI fistula volume measurement was feasible (median acquisition time 207 seconds, IQR 116-250). Volume was associated with disease severity, increasing across TOpClass strata (P < .001). ROC-derived volume thresholds effectively differentiated classes (AUROC 0.69-0.80). A ≥ 27% volume reduction was associated with clinical improvement (AUROC 0.78; sensitivity 64%, specificity 84%).
conclusionsMRI fistula volume is associated with pfCD class and disease trajectory. Volume thresholds are associated with classification shifts and clinical response, supporting their potential as objective quantitative tools. Prospective multicenter validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.